Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    Eli Lilly hits $1 trillion market value, first for health care company

    AdminBy AdminNovember 21, 2025 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Eli Lilly hits $1 trillion market value, first for health care company

    A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.

    Scott Olson | Getty Images

    Eli Lilly reached a $1 trillion market capitalization on Friday, the first health-care company in the world to join the exclusive club dominated by tech firms.

    Eli Lilly briefly hit the $1 trillion mark in morning trading before retreating. It was last trading around $1,048 a share. Eli Lilly is the second nontechnology company to reach the coveted $1 trillion mark in the U.S. after Warren Buffett‘s Berkshire Hathaway.

    The drugmaker’s stock has climbed more than 36% this year as investors applaud the gains it has made over chief rival Novo Nordisk in the GLP-1 drug space. The Indianapolis-based company’s stock has been riding the skyrocketing popularity of its weight loss injection Zepbound and diabetes treatment Mounjaro.

    Stock Chart IconStock chart icon

    hide content

    Eli Lilly’s stock has soared on the back of the success of its drugs Mounjaro and Zepbound.Demand is only expected to grow as approvals for the treatments’ uses and insurance coverage expand.

    The two drugs have driven eye-popping sales growth for Eli Lilly. Last month, the company said Mounjaro drew in $6.52 billion in revenue in the third quarter, a 109% increase from the previous year. Meanwhile, Zepbound posted $3.59 billion in sales during the period, a 184% spike from the prior-year period.

    Demand for the treatments will only grow as approvals for their use and insurance coverage expand. In addition, Eli Lilly expects an oral version of its popular drugs to hit the market next year, which could give patients a more convenient option than a shot that is easier for the company to produce.

    Eli Lilly will likely remain a dominant player in the weight loss drug market, which some analysts believe could be worth more than $150 billion by the early 2030s.

    But despite its recent struggles and leadership shake-ups, Novo Nordisk remains a formidable rival for Eli Lilly in the space. Pfizer also made a push forward in the market, as well, when it won a $10 billion bidding war with Novo Nordisk for obesity drugmaker Metsera earlier this month.

    The runaway success of Zepbound, Mounjaro

    Eli Lilly, a pharmaceutical chemist and Union veteran of the U.S. Civil War, founded his namesake company in 1876. It has long been at the forefront of the diabetes treatment space, introducing the world’s first commercial insulin in 1923. 

    Eli Lilly became a publicly traded company on the New York Stock Exchange by 1952, and for decades relied on a slate of widely successful products to drive much of its profits and revenue. That included insulins, the antidepressant pill Prozac and the earliest polio vaccine. 

    An Eli Lilly & Co. Zepbound injection pen, March 28, 2024.

    Bloomberg | Bloomberg | Getty Images

    Eli Lilly hit the jackpot with the May 2022 approval of tirzepatide for diabetes, which is sold as Mounjaro. It started to compete with Novo Nordisk’s diabetes injection Ozempic, which had entered the market a few years earlier. 

    But Eli Lilly brought a new way to treat diabetes and eventually, obesity. Tirzepatide works by imitating two hormones produced in the gut called GLP-1 and GIP. GLP-1 helps reduce food intake and appetite. GIP, which also suppresses appetite, may also improve how the body breaks down sugar and fat.

    Meanwhile, Novo Nordisk’s semaglutide, the active ingredient in Ozempic and its weight loss drug Wegovy, only targets GLP-1. 

    Mounjaro achieved “blockbuster” status — meaning it generated more than $1 billion in annual sales — during its first full year on the market. Eli Lilly then won approval in late 2023 for tirzepatide as a treatment for obesity, which is sold as Zepbound and now competes with Novo Nordisk’s Wegovy. 

    By 2024, Mounjaro pulled in $11.54 billion in sales, while Zepbound posted $4.93 billion in revenue.

    More CNBC health coverage

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Over 314,000 older Toyota and Lexus vehicles recalled for potentially dangerous airbag issue

    November 20, 2026

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026
    Popular Posts

    Bruno Mars Mourns His Fathers Death: The Man That Taught Me Everything I Know

    RHONJ Fans Less Than Impressed With Season 15 Sneak Peek

    Director Steve Miner Has Shot New Friday the 13th Movie

    JPMorganChase reports cyberattack on third-party service providers

    Fantasy and Science Fiction Books Where the Rules Dont Apply – NewInBooks

    Book Riots Deals of the Day for November 19, 2026

    Categories
    • Books (2,459)
    • Business (3,450)
    • Events (34)
    • Film (1,064)
    • LifeStyle (2,924)
    • Music (2,798)
    • Politics (2,356)
    • Science (1,954)
    • Technology (1,819)
    • Television (3,630)
    • US News (3,295)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Costco adds platinum bars to its precious metals lineupCostco adds platinum bars to its precious metals lineup
    • Best Womens, Mens, Kids Fashion DealsBest Womens, Mens, Kids Fashion Deals
    • Dems tread cautiously around Trump impeachment after Iran strikesDems tread cautiously around Trump impeachment after Iran strikes
    • Polygon Labs Team With Immutable, King River Capital to Announce Inevitable Games FundPolygon Labs Team With Immutable, King River Capital to Announce Inevitable Games Fund
    • Madewell Is Offering Serious Savings Right NowMadewell Is Offering Serious Savings Right Now
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.